Johnson David Ian
Known title: Executive ChairmanCIK: 0001563432
Associated companies
Transaction History
| AIFF | ▲ Buy | Grant | 557,885 | $0 | 10/22/2024 | View on chart |
| AIFF | ▲ Buy | Grant | 557,885 | $0 | 10/22/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Firefly Neuroscience Partners with Neurosigma for Pediatric ADHD Care
Firefly Neuroscience announced a partnership with Neurosigma to expand non-drug treatment options for pediatric ADHD. This move aims to broaden the company's clinical reach in the neurotechnology sector. The stock is currently trading within its 52-week range, with recent volume reflecting interest in this strategic development.
Firefly Neuroscience Partners with Neurosigma for Pediatric ADHD Care. Firefly Neuroscience announced a partnership with Neurosigma to expand non-drug treatment options for pediatric ADHD. This move aims to broaden the company's clinical reach in the neurotechnology sector. The stock is currently trading within its 52-week range, with recent volume reflecting interest in this strategic development.